前收市價 | 8.41 |
開市 | 8.25 |
買盤 | 8.17 x 100 |
賣出價 | 8.64 x 100 |
今日波幅 | 8.08 - 8.80 |
52 週波幅 | 3.21 - 10.69 |
成交量 | |
平均成交量 | 99,067 |
市值 | 123.097M |
Beta 值 (5 年,每月) | 無 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -0.79 |
業績公佈日 | 無 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 13.00 |
Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for low-dose interleukin 2 (ld IL-2) in patients with Alzheimer's disease (AD). The study enrolled eight patients with confirmed brain amyloid pathology and baseline Mini-Mental State Examination test (MMSE) scores, a measure of cognitive function, between 12 and 25. The patients were treated with five-day courses of subcutaneous ld IL-2 for four monthly cycles and were followed for two month
Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for COYA 301 in patients with Alzheimer's disease. Treatment with COYA 301 resulted in a statistically significant improvement in cognitive function, as measured by the Mini-Mental State Examination test (MMSE), compared to the mean MMSE score at baseline (p=0.015). Consistent with the positive trend in MMSE score, mean scores in ADAS-Cog and CDR-SB scales did not significantly change at the